Abstract CC04-01: First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
Keyword(s):
Phase I
◽
2014 ◽
Vol 32
(4)
◽
pp. 653-660
◽
2008 ◽
Vol 63
(6)
◽
pp. 1147-1156
◽
2013 ◽
Vol 19
(15)
◽
pp. 4262-4272
◽